Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

News Daily News

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

February 06, 2026

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

August 05, 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

April 06, 2024

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

July 25, 2022

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

News Daily News

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

June 23, 2022

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

July 02, 2018

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

News Conference News

CANVAS Analysis Provides Heart Failure Reassurances for Canagliflozin

Michael O'Riordan

March 16, 2018

News Daily News

Women vs. Men in BARI 2D: Equal Survival but Worse Quality of Life

March 09, 2013

News Daily News

Mujeres frente a Hombres en el BARI 2D: Misma Supervivencia pero Peor Calidad de Vida

March 09, 2013

News Daily News

BARI 2D: Prompt Revascularization Improves Angina Symptoms in Diabetics

April 01, 2011

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.